Otsuka Reaches $900M Deal For Oncology Drug Co. Astex

Law360, Los Angeles (September 4, 2013, 6:46 PM EDT) -- Japanese drugmaker Otsuka Holdings Co. Ltd. will buy California-based oncology drug developer Astex Pharmaceuticals Inc. for an estimated 90 billion yen ($900 million), according to a Wednesday report.

The acquisition is part of Otsuka's efforts to bolster its future earnings by focusing on potential cancer drugs, Nikkei reported.

Astex stock rose 23.8 percent, to $8.27 per share, on the Nasdaq on Wednesday.

The news comes roughly a month after Otsuka subsidiary Otsuka Techno Corp. said it and Nanjin Otsuka Techbond Techno Co. Ltd. would take an...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.